NIH-NCI (R21 CA198392), “A cancer-targeted phospholipid ether analog for molecular radiotherapy of pediatric solid tumors” (2015-2017). Otto, PI.
Midwest Athletes Against Childhood Cancer, “Effect of zoledronate on engraftment and t-cell development after TCR alpha-ß/CD19-depleted hematopoietic stem cell transplantation” (2015-2017). Otto, PI
Midwest Athletes Against Childhood Cancer, “Clr1404 - A tumor-selective alkyl phospholipid analog for the treatment of pediatric solid malignancies” (2015-2017). Otto, PI
AACR-St. Baldrick’s-SU2C Foundations “Immunogenomics to create new therapies for high-risk childhood cancers” (2013-2017). Otto, Young Investigator
Midwest Athletes Against Childhood Cancer, “Alpha/beta t-cell depleted haploidentical transplantation with post-transplant zoledronic acid to treat recurrent or refractory pediatric malignancies” (2013-2015). Otto, Co-Investigator
Midwest Athletes Against Childhood Cancer, “Development of multifunctional superparamagnetic anti-GD2 nanoparticles for simultaneous molecular imaging, cancer cell targeting and drug delivery” (2011-2015). Otto, PI
Alex’s Lemonade Stand Foundation for Childhood Cancer, “Development of an innovative treatment strategy for neuroblastoma and other pediatric tumors: a novel phospholipid ether analogue and its multifunctional cancer-targeting nanoconstruct” (2012-2014). Otto, PI